KoNECT Talkshow: What Defines Success In New Drug Development?
Patient, Social Value Key Considerations
Executive Summary
At a recent conference in Seoul, senior executives shared views on a broad array of topics around developing globally successful new drugs in an extremely competitive environment, including what could be considered as success. Awareness of patient needs and social value emerged as some key threads.
You may also be interested in...
How Do Bioventures Thrive In APAC? Strategies And Risks Beyond Borders
With the global market in sight, several Asian bioventures discussed at BioJapan event recent projects, strategies and challenges in expanding their businesses in APAC. The different characteristics of policies by country and facets of venture capital funding were some of the topics when speakers talked about “what's the ideal collaboration between Asian bioventures?”
BIORCHESTRA On Overcoming Challenges For miRNA Therapeutics In Neurodegeneration
After being selected as an awardee of J&J’s Innovation QuickFire Challenge On Neuroscience in June, Korean bioventure BIORCHESTRA has been attracting attention from the global neuroscience community. CEO Branden Ryu talks to Scrip what makes its technology unique and how it aims to meet major unmet needs in RNA therapeutics and neurodegenerative disorders.
Celltrion Antibody Becomes First Home-Grown COVID-19 Drug Approval In Korea
Helped by government support for the development of COVID-19 drugs and vaccines, Celltrion’s monoclonal antibody becomes the first therapeutic for the disease to be officially approved in South Korea.